of the Clinical Problem Hypertension is a leading risk factor for mortality and disability. Recent estimates are that 874 million adults worldwide have an SBP of 140 mm Hg or higher.1,2 With its association with CVD, stroke (cerebrovascular accident [CVA]), heart failure, and chronic kidney disease (CKD), hypertension is second only to cigarette smoking as a preventable cause of death in the United States.3 Given demographic trends and the increasing prevalence of hypertension with increasing age (79% of men and 85% of women >75 years old have hypertension), the consequences of hypertension are expected to increase.1,2 Characteristics of the Guideline Source This guideline was developed by the ACC and the AHA in partnership with other professional societies. The ACC/AHA Task Force on Clinical Practice Guidelines selected a writing committee that was notable for its inclusion of people with a breadth of backgrounds, wide scope of practice, and freedom from conflicts of interest. This writing committee reviewed the relevant evidence and commissioned an independent evidence review committee to conduct formal systematic reviews regarding 4 questions of critical importance. The guideline document was reviewed by individuals representing the partner specialty societies and other content reviewers. The writing committee was aware of any conflicts of interest among reviewers (Table). Viewpoint page 2073 and Editorial page 2083

中文翻译：

---

成人高血压的预防、检测、评估和管理

临床问题 高血压是导致死亡和残疾的主要危险因素。最近的估计是，全球有 8.74 亿成年人的 SBP 为 140 毫米汞柱或更高。 1,2 高血压与 CVD、中风（脑血管意外 [CVA]）、心力衰竭和慢性肾病（CKD）有关，因此高血压位居第二3 考虑到人口趋势和高血压患病率随着年龄的增长而增加（75 岁以上的男性和 85% 的女性患有高血压），高血压的后果1,2 指南来源的特征 本指南是由 ACC 和 AHA 与其他专业协会合作制定的。ACC/AHA 临床实践指南工作组选择了一个编写委员会，该委员会因其包含具有广泛背景、广泛实践范围和无利益冲突的人员而著称。该编写委员会审查了相关证据，并委托独立的证据审查委员会对 4 个至关重要的问题进行正式的系统审查。指南文件由代表合作伙伴专业协会的个人和其他内容审查者审查。编写委员会了解审稿人之间的任何利益冲突（表）。观点页 2073 和编辑页 2083 该编写委员会审查了相关证据，并委托独立的证据审查委员会对 4 个至关重要的问题进行正式的系统审查。指南文件由代表合作伙伴专业协会的个人和其他内容审查者审查。编写委员会了解审稿人之间的任何利益冲突（表）。观点页 2073 和编辑页 2083 该编写委员会审查了相关证据，并委托独立的证据审查委员会对 4 个至关重要的问题进行正式的系统审查。指南文件由代表合作伙伴专业协会的个人和其他内容审查者审查。编写委员会了解审稿人之间的任何利益冲突（表）。观点页 2073 和编辑页 2083